Oxygen Biotherapeutics (OXBT) 4.99 $OXBT
Oxygen Biotherapeutics Late-Stage Clinical Trials Could Bode Well for Shareholders Analyst Reports
PR Newswire - Mon May 12, 6:00AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) Today, approximately 8% of the world's population is over the age of 65; and that number is expected to double in less than 40 years. As the world's population ages in the coming years, the demand for critical care services will undoubtedly increase in both developed and underdeveloped countries across the world. In fact, GBI Research estimates that the size of this market will grow from $2.3 billion in 2012 to $3.2 billion in 2019.
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Oxygen Biotherapeutics, Inc. Analyst Report: Positive FDA Catalyst Has Emerging Biopharmaceutical Player Back In the Clinical Trial Business
PR Newswire - Mon Apr 21, 6:00AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), an emerging competitor, is engaged in the business of developing biotechnology products in the nature of blood substitutes with a focus on oxygen delivery to tissue. It is currently developing Oxycyte(TM), a product which is a safe and effective oxygen carrier for use in surgical and similar medical situations. The Company's Oxycyte oxygen carrier product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously.
Oxygen Biotherapeutics Inc., Announces the Appointment of Industry Veteran Gerald Proehl to its Board of Directors
Business Wire - Fri Apr 04, 7:00AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has appointed Gerald Proehl, former President and CEO of Santarus, Inc. as a member of the company's Board of Directors. Mr. Proehl's addition is a new position on the company's Board.
Oxygen Biotherapeutics Up on FDA News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 2:13PM CDT
Clinical hold on Oxycyte has been lifted by the FDA.
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Mon Mar 31, 7:31AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has received written confirmation from the Food and Drug Administration (FDA) that the clinical hold on the Oxycyte development program has been lifted.
Oxygen Biotherapeutics prices public offering at USD5.60 per share
M2 - Wed Mar 19, 6:04AM CDT
Pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) disclosed on Tuesday that it has priced a public offering of its common stock at USD5.60 per share.
Oxygen Biotherapeutics Prices $52 Million Underwritten Offering
Business Wire - Tue Mar 18, 7:45AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has priced an underwritten public offering of shares of common stock at a public offering price of $5.60 per share for gross proceeds of approximately $52 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 1,392,857 shares of common stock to cover over-allotments, if any.
Oxygen Biotherapeutics to issue common stock in public offering
M2 - Tue Mar 18, 6:37AM CDT
US-based pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) said on Monday that it intends to start a public offering of its common stock.
Oxygen Biotherapeutics Announces Proposed Public Offering
Business Wire - Mon Mar 17, 3:05PM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds received from the offering for furthering its clinical trials and efforts to obtain regulatory approval for Levosimendan and Oxycyte, developing its other product candidates, supporting manufacturing of Levosimendan and Oxycyte, research and development and general corporate purposes.
OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
WEALTHMAKERS.COM Issues Report on Oxygen Biotherapeutics
M2 - Thu Mar 06, 7:27AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Oxygen Biotherapeutics (NASDAQ: OXBT). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.12 and the projected fundamental target of $10.50 per share.
Technical Notes on Top Gainers: Vipshop Holdings, Oxygen Biotherapeutics, JinkoSolar Holding, SunPower and BPZ Resources
PR Newswire - Wed Mar 05, 9:18AM CST
The US markets saw a positive sentiment on Tuesday, March 04, 2014, as the NASDAQ Composite closed at 4,351.97, climbing 1.75%, the Dow Jones Industrial Average ended the session at 16,395.88, up 1.41% and the S&P 500 edged 1.53% higher to finish the bullish trading session at 1,873.91. During the session healthy gains in the Financial, Health Care and Materials sectors positively impacted the broader market. A number of stocks saw large movements, including Vipshop Holdings Ltd (NYSE: VIPS), Oxygen Biotherapeutics Inc. (NASDAQ: OXBT), JinkoSolar Holding Company Ltd (NYSE: JKS), SunPower Corporation (NASDAQ: SPWR), and BPZ Resources Inc. (NYSE: BPZ), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
5 Stocks Ready to Explode Higher
at The Street - Wed Feb 26, 2:03PM CST
Here's a look at five stocks with potentially explosive chart patterns.
Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Newly Published Cardiac Surgery Study Provides Further Evidence that Levosimendan Significantly Improves Post-operative Kidney Function.
Business Wire - Thu Feb 13, 7:00AM CST
Oxygen Biotherapeutics, Inc., ("OBI"
(NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that a recently published study in the Journal of Cardiothoracic and Vascular Anesthesia provides evidence that levosimendan provides significant renal benefits to patients undergoing mitral valve surgery. The study was a double blinded, randomized, controlled trial of 128 patients with low ejection fraction (EF<45%) undergoing mitral valve surgery. As the authors reference, patients with low ejection fraction undergoing mitral valve surgery are at risk for adverse outcomes, including a significant risk for acute kidney injury. A link to access "In Press" version of this publication is found here http://www.jcvaonline.com/article/S1053-0770(...9/fulltext
Staffordshire University: University Relocation Decision is in Best Interests of Students
Business Wire - Thu Jan 30, 1:35AM CST
Staffordshire University has announced plans to deliver the majority of its courses from one main campus in Stoke-on-Trent.
Oxygen Biotherapeutics Late-Stage Clinical Trials Could Bode Well for Shareholders Analyst Reports
PR Newswire - Mon May 12, 6:00AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) Today, approximately 8% of the world's population is over the age of 65; and that number is expected to double in less than 40 years. As the world's population ages in the coming years, the demand for critical care services will undoubtedly increase in both developed and underdeveloped countries across the world. In fact, GBI Research estimates that the size of this market will grow from $2.3 billion in 2012 to $3.2 billion in 2019.
Traumatic Brain Injury - Pipeline Review, H1 2014: Includes 42 Company and 72 Drug Profiles
M2 - Mon May 12, 5:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vqxgvm/traumatic_brain) has announced the addition of the "Traumatic Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Traumatic Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - ALSP, Inc. - Acorda Therapeutics, Inc. - Adamas Pharmaceuticals, Inc. - Allinky Biopharma - Amarantus Bioscience Holdings, Inc. - Athersys, Inc. - BHR Pharma, LLC - Bionature E.A. Ltd. - Cognosci, Inc. - Concert Pharmaceuticals, Inc. - D-Pharm Ltd. - Encore Therapeutics Inc. - Euroscreen S.A. - Grupo Ferrer Internacional, S.A. - Intellect Neurosciences, Inc. - Io Therapeutics, Inc. - Lixte Biotechnology Holdings, Inc. - Lpath, Inc. - M's Science Corporation - MAPREG - MandalMed, Inc. - Mnemosyne Pharmaceuticals, Inc. - NeoStem, Inc. - Neuralstem, Inc. - Neuren Pharmaceuticals Limited - NeuroHealing Pharmaceuticals Inc. - NeuroNascent, Inc. - NeuroVive Pharmaceutical AB - Omeros Corporation - Oxygen Biotherapeutics, Inc. Drug Profiles: - epoetin alfa - progesterone - progesterone - NeuroSTAT - Oxycyte - VAS-203 - NH-001 - NNZ-2566 - atorvastatin calcium - NeuroSTAT - glyburide - Allopregnanolone - VOLT-02 - SB-623 - RGS-2064 - DP-b99 - amantadine hydrochloride - Drug for Traumatic Brain Injury - MAP-4343 - Posiphen - MultiStem - Lpathomab - RGN-352 - cutamesine - INN-01 - NSI-189 - COG-1410 - AMR-001 - NSI-566 - LB-201 For more information visit http://www.researchandmarkets.com/research/vq...atic_brain
Oxygen Biotherapeutics, Inc. Analyst Report: Positive FDA Catalyst Has Emerging Biopharmaceutical Player Back In the Clinical Trial Business
PR Newswire - Mon Apr 21, 6:00AM CDT
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), an emerging competitor, is engaged in the business of developing biotechnology products in the nature of blood substitutes with a focus on oxygen delivery to tissue. It is currently developing Oxycyte(TM), a product which is a safe and effective oxygen carrier for use in surgical and similar medical situations. The Company's Oxycyte oxygen carrier product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously.
Oxygen Biotherapeutics Inc., Announces the Appointment of Industry Veteran Gerald Proehl to its Board of Directors
Business Wire - Fri Apr 04, 7:00AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has appointed Gerald Proehl, former President and CEO of Santarus, Inc. as a member of the company's Board of Directors. Mr. Proehl's addition is a new position on the company's Board.
Oxygen Biotherapeutics Up on FDA News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 2:13PM CDT
Clinical hold on Oxycyte has been lifted by the FDA.
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program
Business Wire - Mon Mar 31, 7:31AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has received written confirmation from the Food and Drug Administration (FDA) that the clinical hold on the Oxycyte development program has been lifted.
Oxygen Biotherapeutics prices public offering at USD5.60 per share
M2 - Wed Mar 19, 6:04AM CDT
Pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) disclosed on Tuesday that it has priced a public offering of its common stock at USD5.60 per share.
Oxygen Biotherapeutics Prices $52 Million Underwritten Offering
Business Wire - Tue Mar 18, 7:45AM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today that it has priced an underwritten public offering of shares of common stock at a public offering price of $5.60 per share for gross proceeds of approximately $52 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has also granted the underwriters a 45-day option to purchase up to an additional 1,392,857 shares of common stock to cover over-allotments, if any.
Oxygen Biotherapeutics to issue common stock in public offering
M2 - Tue Mar 18, 6:37AM CDT
US-based pharmaceutical company Oxygen Biotherapeutics (NasdaqCM:OXBT) said on Monday that it intends to start a public offering of its common stock.
Oxygen Biotherapeutics Announces Proposed Public Offering
Business Wire - Mon Mar 17, 3:05PM CDT
Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, announced today its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds received from the offering for furthering its clinical trials and efforts to obtain regulatory approval for Levosimendan and Oxycyte, developing its other product candidates, supporting manufacturing of Levosimendan and Oxycyte, research and development and general corporate purposes.
OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
WEALTHMAKERS.COM Issues Report on Oxygen Biotherapeutics
M2 - Thu Mar 06, 7:27AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Oxygen Biotherapeutics (NASDAQ: OXBT). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $5.12 and the projected fundamental target of $10.50 per share.
Technical Notes on Top Gainers: Vipshop Holdings, Oxygen Biotherapeutics, JinkoSolar Holding, SunPower and BPZ Resources
PR Newswire - Wed Mar 05, 9:18AM CST
The US markets saw a positive sentiment on Tuesday, March 04, 2014, as the NASDAQ Composite closed at 4,351.97, climbing 1.75%, the Dow Jones Industrial Average ended the session at 16,395.88, up 1.41% and the S&P 500 edged 1.53% higher to finish the bullish trading session at 1,873.91. During the session healthy gains in the Financial, Health Care and Materials sectors positively impacted the broader market. A number of stocks saw large movements, including Vipshop Holdings Ltd (NYSE: VIPS), Oxygen Biotherapeutics Inc. (NASDAQ: OXBT), JinkoSolar Holding Company Ltd (NYSE: JKS), SunPower Corporation (NASDAQ: SPWR), and BPZ Resources Inc. (NYSE: BPZ), which were amongst the top gainers for the session. Free research on these five companies can be accessed at:
5 Stocks Ready to Explode Higher
at The Street - Wed Feb 26, 2:03PM CST
Here's a look at five stocks with potentially explosive chart patterns.
Research and Markets: Panel Builders Market: Research & Analysis UK 2014-2018
Business Wire - Thu Feb 20, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/5b4nzh/panel_builders) has announced the addition of the "Panel Builders Market: Research & Analysis UK 2014-2018" report to their offering.
Biotech Breakthroughs Brings Powerful Cancer Testing and Drugs to Market
PR Newswire - Tue Feb 18, 6:00AM CST
New trial confirms MetaSite Breast test's ability to predict breast cancer metastasis. MetaSite Breast would allow doctors and patients to customize breast cancer treatment based on the cancer's probability of metastasizing.
Newly Published Cardiac Surgery Study Provides Further Evidence that Levosimendan Significantly Improves Post-operative Kidney Function.
Business Wire - Thu Feb 13, 7:00AM CST
Oxygen Biotherapeutics, Inc., ("OBI"
(NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that a recently published study in the Journal of Cardiothoracic and Vascular Anesthesia provides evidence that levosimendan provides significant renal benefits to patients undergoing mitral valve surgery. The study was a double blinded, randomized, controlled trial of 128 patients with low ejection fraction (EF<45%) undergoing mitral valve surgery. As the authors reference, patients with low ejection fraction undergoing mitral valve surgery are at risk for adverse outcomes, including a significant risk for acute kidney injury. A link to access "In Press" version of this publication is found here http://www.jcvaonline.com/article/S1053-0770(...9/fulltext Staffordshire University: University Relocation Decision is in Best Interests of Students
Business Wire - Thu Jan 30, 1:35AM CST
Staffordshire University has announced plans to deliver the majority of its courses from one main campus in Stoke-on-Trent.
